Shire Submits Investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A

July 7, 2017

Note: The following is an edited version of a press release from Shire. Read the press release from Shire in it’s entirety here. Shire has announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for SHP654, also designated as BAX 888, an investigational factor VIII (FVIII) gene therapy for the […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.